Nishimura Shuichi, Takeda Atsuya, Sanuki Naoko, Kawase Takatsugu, Tsukamoto Nobuhiro
Department of Radiation Oncology, Saitama City Hospital, Saitama, JPN.
Department of Radiology, Keio University School of Medicine, Tokyo, JPN.
Cureus. 2025 Apr 27;17(4):e83094. doi: 10.7759/cureus.83094. eCollection 2025 Apr.
Determining the optimal treatment for patients with huge hepatocellular carcinoma (HCC) remains challenging. Although surgical resection is the preferred option, it is feasible only in selected cases. Transarterial chemoembolization is commonly used but often provides insufficient local control. Advanced radiation therapy methods, such as real-time tumor tracking and inverse planning, have enabled the safe delivery of high-dose radiation via stereotactic body radiotherapy (SBRT), achieving excellent local control. However, alternative strategies may be necessary for difficult cases. We report the case of an 81-year-old male with a 12-cm unresectable HCC who was successfully treated with two-stage CyberKnife SBRT. Due to the tumor size and proximity to the gastrointestinal tract, single-stage SBRT was considered infeasible. The first-stage SBRT (25 Gy in three fractions, maximum dose of 55 Gy) induced tumor shrinkage, allowing for the second-stage SBRT (25 Gy in five fractions, maximum dose of 50 Gy) six months later. The only adverse event was transient radiation-induced fatigue two weeks post-treatment. A significant reduction in tumor volume was achieved, with no recurrence and preserved liver function for 44 months after initial treatment. This case highlights the potential of two-stage SBRT with real-time tumor tracking as an effective treatment strategy for unresectable huge HCC.
确定巨大肝细胞癌(HCC)患者的最佳治疗方案仍然具有挑战性。尽管手术切除是首选方案,但仅在特定病例中可行。经动脉化疗栓塞术常用,但往往提供的局部控制不足。先进的放射治疗方法,如实时光学肿瘤追踪和逆向计划,已能够通过立体定向体部放射治疗(SBRT)安全地给予高剂量辐射,实现出色的局部控制。然而,对于困难病例可能需要其他策略。我们报告了一例81岁男性,患有12厘米不可切除的HCC,通过两阶段射波刀SBRT成功治疗。由于肿瘤大小及与胃肠道的接近程度,单阶段SBRT被认为不可行。第一阶段SBRT(分三次给予25 Gy,最大剂量55 Gy)使肿瘤缩小,六个月后可行第二阶段SBRT(分五次给予25 Gy,最大剂量50 Gy)。唯一的不良事件是治疗后两周出现短暂的放射性疲劳。肿瘤体积显著减小,初始治疗后44个月无复发且肝功能得以保留。该病例突出了采用实时光学肿瘤追踪的两阶段SBRT作为不可切除巨大HCC有效治疗策略的潜力。